Osmotica Pharmaceuticals PLC $ 5.59 -0.09 (-1.58%)
Volume:
213,185
Avg Vol (1m):
720,941
Market Cap $:
328.45 Mil
Enterprise Value $:
475.65 Mil
P/E (TTM):
0.00
P/B:
2.29
Financial Strength | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.46 | ||
| Equity-to-Asset | 0.3 | ||
| Debt-to-Equity | 1.9 | ||
| Debt-to-EBITDA | -1.19 | ||
| Interest Coverage | 0.44 | ||
| Altman Z-Score | -1.59 | ||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 3.34 | ||
| Net Margin % | -115.34 | ||
| ROE % | -128.49 | ||
| ROA % | -46.81 | ||
| ROC (Joel Greenblatt) % | -642.57 | ||
| 3-Year Revenue Growth Rate | -3.5 | ||
| 3-Year EBITDA Growth Rate | -179.9 | ||
| 3-Year EPS without NRI Growth Rate | -74.3 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.29 | ||
| PS Ratio | 1.31 | ||
| Price-to-Free-Cash-Flow | 8.28 | ||
| Price-to-Operating-Cash-Flow | 7.39 | ||
| EV-to-EBIT | -1.75 | ||
| EV-to-EBITDA | -2.06 | ||
| EV-to-Revenue | 2.05 | ||
| Current Ratio | 3.26 | ||
| Quick Ratio | 2.91 | ||
| Days Inventory | 88.42 | ||
| Days Sales Outstanding | 51.46 | ||
| Days Payable | 31.12 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Earnings Yield (Greenblatt) % | -57.76 |